Blauvelt, A. ., P. Rich, H. Sofen, J. Lambert, J. Merola, M. Lebwohl, L. Hippeli, R. Kisa, S. Banerjee, and A. Kimball. “Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis: Subset Analyses of the Phase 3 POETYK PSO-1 and PSO-2 Trials”. SKIN The Journal of Cutaneous Medicine, vol. 6, no. 4, July 2022, p. s41, doi:10.25251/skin.6.supp.41.